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Background: The growing interest in the role of epigenetic modifications in human health and disease has led to
the development of next-generation sequencing methods for whole genome analysis of DNA methylation patterns.
However, many projects require targeted methylation analysis of specific genes or genomic regions. We have
developed an approach, termed BiSulfite Amplicon Sequencing (BSAS), for hypothesis driven and focused absolute
DNA methylation analysis. This approach is applicable both to targeted DNA methylation studies as well as to
confirmation of genome-wide studies.
Results: BSAS uses PCR enrichment of targeted regions from bisulfite-converted DNA and transposome-mediated
library construction for rapid generation of sequencing libraries from low (1 ng) sample input. Libraries are
sequenced using the Illumina MiSeq benchtop sequencer. Generating high levels of sequencing depth (>1,000 ×)
provides for quantitatively precise and accurate assessment of DNA methylation levels with base specificity. Dual
indexing of sequencing libraries allows for simultaneous analysis of up to 96 samples. We demonstrate the superior
quantitative accuracy of this approach as compared to existing Sanger sequencing methods.
Conclusions: BSAS can be applied to any genomic region from any DNA source, including tissue and cell culture.
Thus, BSAS provides a new validation approach for rapid and highly quantitative absolute CpG methylation analysis
of any targeted genomic regions in a high throughput manner.
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Epigenetic modifications, both histone modifications and
DNA modifications (cytosine methylation and hydroxy-
methylation), are key regulators of the genomic structure
and gene expression. Cytosine methylation in the CpG
dinucleotide motif is essential for normal mammalian
development [1] and control of imprinted genes [2]. The
cytosines contained in CpG motifs are targeted for
methylation on the 5-carbon site, often denoted as 5-
methylcytosine, or 5-mC. CpG motifs are found through-
out the genome, but at a lower frequency then would be
expected by chance, and are often observed in clusters* Correspondence: wfreeman@hmc.psu.edu
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reproduction in any medium, provided the orknown as CpG islands [3]. Functionally, cytosine methy-
lation is thought to regulate chromatin status and dir-
ectly affect the ability of transcription factors to access
DNA. Generally, in the context of gene promoters, hypo-
methylated CpGs are associated with active, constitutively
expressed genes, while hypermethylated CpGs are associ-
ated with silenced genes [4].
A number of methods to assess and quantify DNA
methylation at a genome-wide level, using either micro-
arrays or sequencing, have been reviewed previously
[5]. With the development of low-cost, high-output
next-generation sequencing (NGS), 5-mC quantitation
methods have predominantly transitioned to sequencing
approaches. Many of the sequencing approaches utilize
bisulfite conversion to differentiate methylated from un-
methylated cystosines with base resolution [6,7]. Expos-
ing DNA to sodium bisulfite deaminates unmethylated
cytosines into uracil and these uracils are then replacedLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sines, however, are protected from sulfonation and are not
converted. Therefore, in sequence analysis of bisulfite-
converted DNA, methylated cytosines appear as cytosine
and unmethylated cytosines appear as thymines. Bisulfite
DNA conversion and whole genome NGS provide wide
coverage across the methylome. Whole methylome ana-
lyses remain complex, and resource intensive, which has
also led to development of sequence enrichment strat-
egies with antibodies or oligonucleotides (for example,
MeDIP-seq, MethylCap), or digesting DNA with methy-
lation sensitive restriction enzymes coupled to bisulfite
conversion (reduced representation bisulfite sequencing
(RRBS)) [5]. For highly targeted analyses (that is, selected
genomic regions such as gene promoters, or validation of
targeted regions from whole methylome analyses), trad-
itional approaches of pyrosequencing or Sanger sequencing
still predominate [8-11]. For hypothesis driven analyses,
pyrosequencing and Sanger methods, while useful, are lim-
ited in their quantitative accuracy, read length and sample
throughput. The quantitative deficiencies are due in part to
the analog nature of their sequence outputs; light signal in
pyrosequencing and fluorescent traces with Sanger sequen-
cing and capillary electrophoresis [12].
Combining the benefits of bisulfite conversion, targeted
amplification, tagmentation-based library construction and
NGS we have developed a novel method, termed BiSulfite
Amplicon Sequencing (BSAS), for targeted digital quanti-
tation of DNA methylation. Utilizing BSAS, we validated
the precision and accuracy of the method by targeted pro-
moter region analysis in both rat and mouse whole genome
methylation standards. Additionally, we analyzed methyla-
tion levels of known tissue differences in gene expression
and promoter methylation and demonstrate the method’s
ability to corroborate transcript expression levels with pro-
moter methylation levels. These analyses were duplicated
through bisulfite conversion and direct PCR Sanger se-
quencing to compare the performance of BSAS to an
existing method of targeted methylation analysis. The ap-
plication of BSAS is useful in hypothesis-driven epigenetic
studies where regions of interest have been identified, and
provides a rapid, accurate, and cost-effective method to
quantify cytosine methylation with base specificity.
Results
BSAS method validation with rat and mouse
methylation controls
BSAS involves; (1) bisulfite conversion of genomic DNA
to distinguish between methylated and unmethylated cy-
tosines, (2) PCR amplification of regions of interest with
PCR primers specific for converted sequences, (3) trans-
posome mediated (Nextera XT) NGS library preparation
technology, (4) sequencing the amplified regions on a
benchtop sequencer (Illumina MiSeq), (5) alignment toin silico converted reference sequences, and 6) applica-
tion of variant-calling algorithms for counting of cyto-
sines and thymines at CpG sites for quantitative digital
methylation analysis (Figure 1). Enzymatically generated
whole genome rat and mouse methylation standards at
mixed ratios (0, 5, 10, 25, 50, 75 and 100%) were ana-
lyzed for CpG methylation levels using BSAS (Figure 1)
as well as the traditional Sanger sequencing approach
with epigenetic sequencing methylation analysis (ESME).
ESME was developed to eliminate the need for sequen-
cing of multiple cloned amplicons per sample [13]. For
the rat controls the mu opioid receptor, Oprm1, was
used as the example region of interest and for the mouse
standards the rhodopsin, Rho promoter region was ana-
lyzed. The MiSeq sequencing run for the rat standards
produced a total of 4.21 million reads that passed the
initial quality filter. Of these 1.96 million reads were
mapped after overlapping read merging, quality trim-
ming and elimination of PhiX control reads. For the
mouse standards 10.81 million reads passed the quality
filter, and 7.5 million reads were mapped after overlap-
ping read merging, quality trimming and elimination of
PhiX control reads. Bisulfite conversion efficiencies were
confirmed to be >98% by examination of cytosine to thy-
mine conversion for cytosines not in CpG motifs. Stand-
ard curves were generated from each set of methylation
controls by taking the mean methylation level across
the amplified region; 7 CpG sites from the rat controls,
and 13 CpG sites from the mouse controls (Figures 2A
and 3A). Both the rat and mouse standard curve BSAS
data were able to fit linear lines of r2 = 0.99. Standard
curves were also generated from each set of methylation
controls analyzed with Sanger/ESME (Figures 2B and 3B).
The Sanger/ESME control data were also able to fit linear
lines with r2 = 0.90 and 0.73 for the rat and mouse con-
trols, respectively. BSAS, for both sets of controls, was
more accurate in methylation quantitation when com-
pared to the standard curves generated from the Sanger/
ESME method as evidenced from the higher correlation
coefficients from the data generated from BSAS (r = 0.99)
compared to the Sanger/ESME data (r = 0.88 and 0.96
mouse and rat, respectively). The precision of methylation
quantitation was also greater in the data generated from
BSAS when compared to the Sanger/ESME data. This is
evident from the variation in methylation quantitation of
the technical replicates (n = 3 per standard) of the gener-
ated standard curves for both sets of controls in both
methods of methylation quantitation. The standard curves
generated from the Sanger/ESME method have variations
ranging from 5% to over 20% error in quantitation, while
the BSAS method produced variation consistently less
than 5% error.
The average measured methylation levels from both
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Figure 1 Bisulfite amplicon sequencing (BSAS) method schematic. Genomic DNA is bisulfite converted and subjected to bisulfite-specific
PCR, using primers specific for bisulfite converted DNA (bs-F and R red lines). Amplicons are subjected to Nextera XT library preparation including
dual indexing. Final libraries consist of a random insert of bisulfite converted, amplified DNA, capture probes (black and gray) and specific index
sequences (orange, magenta, green, pink). These libraries are multiplexed and sequenced on the Illumina MiSeq. Demultiplexing separates the
dual indexed reads from each sample (orange and magenta are one sample, green and pink represent the other sample). These reads are aligned
to an in silico converted reference sequence, and variant calling is used to identify the percentage of 5-mC.
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rat methylation control sets. BSAS (Figures 2C and 3C)
data was more accurate and less varied at each CpG site
when compared to the Sanger/ESME method (Figures 2D
and 3D). This was evident from the quantitation not over-
lapping at any of the controls at any CpG site for the BSAS
data, while there is significant overlap of methylation quan-
titation across the CpG sites in the Sanger/ESME data.
Additionally, the Sanger/ESME method was not sensitive
enough to ensure all controls were represented at each
CpG site. Because of this, there were missing values in the
plots for the Sanger method.By using whole genome methylation controls in two
species to generate percentage of methylation standard
curves, we demonstrated the ability of BSAS to consistently
and accurately quantify CpG methylation when com-
pared to traditional Sanger/ESME methylation quantita-
tion. Under the assumption that the methylation standards
were correct, mean squared error (MSE) statistical analysis
for comparison of BSAS and Sanger/ESME demonstrated
a 16-fold average increase in methylation quantitation ac-
curacy, or decrease in error, across the mouse methylation
controls. Quantitation of the rat controls yielded a fivefold
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Figure 2 Bisulfite amplicon sequencing (BSAS) and Sanger/epigenetic sequencing methylation (analysis (ESME) methylation
quantitation of whole genome rat methylation controls. (A,B) Standard curves were generated by BSAS and Sanger methylation quantitation
and plotted out with expected percentage of methylation versus the actual quantified methylation. Points represent the mean of the seven CpG
sites analyzed in the Oprm1 promoter from each methylation standard (n = 3/control). Error bars = SD. (C,D) Average measured methylation for
each standard plotted across each CpG site from BSAS and Sanger methylation quantitation (error bars not included for legibility).
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Figure 3 Bisulfite amplicon sequencing (BSAS) and Sanger/epigenetic sequencing methylation analysis (ESME) methylation
quantitation of whole genome mouse methylation controls. (A,B) Standard curves were generated by BSAS and Sanger methylation
quantitation and plotted out with expected percentage of methylation versus the actual quantified methylation. Points represent the mean of
the 13 CpG sites analyzed in the Rho promoter from each methylation standard (n = 3/control). Error bars = SD. (C,D) Average measured
methylation for each standard plotted across each CpG site from BSAS and Sanger methylation quantitation (error bars not included for legibility).
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Table 1 Bisulfite amplicon sequencing (BSAS) accuracy
improvement









Mean squared error (MSE) improvements of methylation quantitation from
BSAS compared to Sanger/epigenetic sequencing methylation analysis (ESME)
from each methylation control are presented. BSAS was more accurate at
quantifying methylation at every control, and demonstrated an overall 16-fold
decrease in error compared to Sanger/ESME across the mouse controls and
5-fold decrease in error across the rat controls.
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in the standard curve from both species. Both methods
were able to measure methylation from each control set,
but BSAS was less varied and more sensitive in methyla-
tion quantitation, as shown by the ability to measure the
percentage of methylation from each control set at each
CpG site.
Rho promoter methylation tissue difference
We used mouse tissue to compare methylation quantita-
tion in a biological scenario between BSAS and Sanger/
ESME. We measured the Rho promoter methylation in
retinal and cerebellar tissue, which contained 13 CpG
sites (n = 4/tissue). Relative Rho mRNA expression, mea-
sured in the two tissues by quantitative PCR (qPCR),
was found to be highly expressed in the retina and not
detectable in the cerebellum (Figure 4A). Using the
BSAS method, the sequencing run produced 8.22 million
reads, and 6.54 million reads were mapped after read
merging, quality trimming, and elimination of PhiX con-
trol reads. Bisulfite conversion efficiencies were confirmed
to be >98%. The mean measured CpG methylation in the
Rho promoter was found to be between 75% to 100%
methylated at every CpG site evaluated in the mouse cere-
bellar tissue (Figure 4B). Conversely, the promoter CpG
methylation in the Rho expressing retinal tissue was be-
tween 0% to 20%. Methylation levels were significantly
higher (P <0.001) in the cerebellum than retina at every
CpG site in the promoter. The same amplicons were se-
quenced using the Sanger/ESME (n = 4/tissue) (Figure 4C).
The methylation levels measured in the cerebellar tissue
were between 60% to 100% methylated, while the levels
measured in the retina were between 0% to 30%. While
BSAS produced statistically different methylation levels be-
tween the two tissues at each CpG site, the Sanger/ESMEmethod did not. There were statistical significant differ-
ences at 10 of the 13 CpG sites measured (P <0.001 to
0.002), while the last 3 sites could not be tested due to
the missing data caused by the lack of sensitivity from
the Sanger/ESME method because of the analog quanti-
tation and sequence coverage. In addition to every CpG
site not being statistically significant, the variation in
methylation quantitation, shown by standard deviation,
was much greater in the Sanger/ESME data with stand-
ard deviation ranging from 5% to 30%. This error was
much smaller in the BSAS methylation data, where there
was at most 5% standard deviation.
Sequence saturation and confidence interval
Overall, validation of BSAS was performed at high se-
quencing read depths (Additional file 1: Figure S2). To
determine the optimal depth of sequencing required
for quantitative accuracy, a binomial theoretical model
was used to measure the confidence interval radius of
methylation quantitation (Additional file 2: Figure S3).
Empirical data visualized with the same model agreed
with the theoretical model, with the average confidence
interval radius difference being 0.00095. In order to assess
the effect of sequencing depth on quantitation accuracy,
we investigated the confidence interval for measuring 50%
5-mC, which based on the binomial theoretical model,
has the largest confidence interval radius, at varying se-
quencing depths (10 to 1,000,000 ×) (Figure 5). The theor-
etical confidence interval shrinks with greater sequencing
depth, as shown for both the rat (Figure 5A) and the
mouse (Figure 5B) methylation controls. Additionally, the
empirical mouse and rat data are represented as horizontal
lines in their respective plots, at average sequencing depths
of 10,000 to 100,000 ×. Based on the confidence interval,
methylation quantitation is not greatly improved at se-
quencing read depths greater than 1,000 ×. Therefore, a se-
quencing depth of ≥1,000 × is sufficient for accurate
methylation quantitation, while quantitation at lower se-
quencing depths might yield less accurate and wider spread
data. Empirically, the rat and mouse data averages are
slightly larger than the expected confidence interval for
50% methylation quantitation. Using a more conservative
approach for calculating the confidence interval, the empir-
ical data is well within the confidence interval radius for
both the rat and mouse controls.
Discussion
BSAS was developed to quantitatively and accurately
measure 5-mC levels in genomic regions of interest. For
many hypothesis-driven investigations or validation of
genome-wide methylation studies, analysis of specific gene
promoters, CpG islands or differentially methylated regions
is needed. Combining existing approaches in bisulfite con-
























































































Figure 4 Rho promoter methylation in mouse retina and cerebellum. (A) Quantitative PCR showed Rho mRNA expression to be high in the
mouse retina (n = 4) while expression was not detected in the mouse cerebellum (n =4). (B) Rho promoter methylation measured by bisulfite
amplicon sequencing (BSAS) in both the cerebellum (white) and the retina (black) across 13 CpG sites in the Rho promoter. (C) Rho promoter
methylation measured by Sanger sequencing in the cerebellum and retina across 13 CpG sites in the Rho promoter. Error bars = SD. ***P <0.001,
**P <0.002; t test.
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customizable approach applicable to a wide variety of epi-
genetic studies. Using BSAS for targeted quantitative DNA
methylation analysis, we demonstrated a 16-fold (mouse
controls) and 5-fold (rat controls) decrease in the error of
methylation quantitation over traditional direct bisulfite
PCR amplicon Sanger sequencing and ESME. Whole gen-
ome DNA methylation standards were used to show this
increase in accuracy of BSAS methylation quantitation
across the dynamic range (from 0% to 100%) over the trad-
itional approach in two regions from rat and mouse ge-












Figure 5 Confidence interval sequencing saturation. The theoretical co
quantitation for measurement of 50% cytosine methylation for both the (A
the empirical data are represented as horizontal lines (black) and the avera
(dashed curves) is also shown, representing the theoretical model with 0.1nattributed to the decrease in quantitation error over the
traditional approach, seen in the standard curves gener-
ated. This decrease in error was most likely due to the
digital quantitation of NGS as opposed to analog nature of
the Sanger sequencing and the sequencing depth achieved
in the BSAS method. Rho promoter methylation differ-
ences corroborated mRNA expression from retina and
cerebellar tissue, with BSAS generating more precise data.
In general, sequencing depth in the BSAS method ranged
from 1,000 × saturation of the targeted region to well over
500,000 × saturation, at any given CpG site measured.












nfidence interval based on the binomial model of methylation
) mouse and (B) rat methylation controls (solid black curves), where
ge of the empirical data (red line). A conservative confidence interval
with n being the actual depth of the experimental data.
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both the rat and mouse sets. Achieving 1,000 × sequencing
depth was sufficient for accurate methylation quantitation.
Using the theoretical model presented, the confidence
interval does not improve significantly at depths greater
than 1,000 ×. Therefore, when designing BSAS experi-
ments, a target of 1,000 × would be a sufficient depth for
accurate methylation quantitation. Our empirical data fit
well within the theoretical model; however, there was a
slight inflation of the confidence interval outside the
expected for both the rat and mouse data sets. The source
of error was most likely the methylation standards. Over-
all, the digital quantitation of BSAS improved the quanti-
tation and statistical power over the Sanger method,
which has an analog output with CpG methylation quanti-
tation being a function of the area under the curves for
the C and T traces. Thus, because BSAS is digital and
reaches sequencing depths required for accurate quantita-
tion, BSAS was superior to the Sanger method.
In addition to the better quantitation with BSAS, there
were multiple benefits of using this method. There was
no need to use sequencing primers as there is in pyro-
sequencing and direct bisulfite amplicon Sanger sequen-
cing, which can limit these methods of sequencing in
the quality of sequence obtained. The use of sequencing
primers also limits these methods to looking at only one
direction of one target region, limiting the throughput
capabilities of pyrosequencing and Sanger sequencing
reactions, and read length. Pyrosequencing is often lim-
ited to shorter reads (approximately 100 bp) requiring
multiple tiled reads to achieve the coverage observed
with BSAS [14]. In BSAS, the sequencing step is random
and unbiased, thus multiple target genomic regions in
one sample, and multiple samples, can be sequenced to-
gether on one flow cell. The use of cloning was not
needed in BSAS; this reduced the overall time of the
method considerably, as well as significantly improving
the ease of library construction. Additionally, because of
the digital nature of BSAS, when quantifying regions of
interest, there is no need to generate a standard curve
for each target. In the analog methods, standard curves
are necessary for quantitation, because the quantitation
is based on an assay signal, or output, not counting. This
greatly reduces the amount of samples that need to be
run with BSAS compared to pyrosequencing or Sanger.
Previously, targeted methylation analysis approaches,
which have incorporated NGS into their protocols, de-
pend on targeting of CpG sites by using hybridization
arrays, padlock probe sets, and capture probes for whole
genome methylation analysis [15-17]. Massively parallel
PCR amplification with the Raindance technology fol-
lowed by NGS has also been described [18]. These
methods are well suited to ‘medium’ scale discovery but
the complexity of the methods, requirement for additionalspecialized equipment and costs limit their application,
especially for highly targeted studies with large numbers
of samples. The BSAS approach only required standard
molecular biology equipment and access to a benchtop
sequencer. Where all of these methods excel is in their
use of NGS for digital methylation quantitation. There
are multiple reports profiling methylomes using NGS on
tissues such as the human placenta [19], cancer cells
[20], rodent animal models [21], rodent animal models
[22], and disease states such as diabetes [22]. These find-
ings break new ground in understanding DNA methyla-
tion across large regions of the genome, but a targeted
approach of methylation analysis, like BSAS, is highly ap-
plicable to quantitative analysis of certain genes or regions,
especially when a large number of samples are required.
In particular, the rapid and cost effective nature of
tagmentation-based library preparation and benchtop se-
quencing make BSAS an easily adopted method. An al-
ternative approach to NGS-based focused methylation
analysis is the MassARRAY mass spectrometry approach
[23]. This approach has been used successfully for a
number of studies but does require specific instrumenta-
tion, and non-sequence data can lead to ambiguity in de-
termining base-specific methylation [24]. Therefore, whole
methylome studies are useful for broad discovery efforts,
while BSAS is a tool for answering hypothesis driven re-
search questions of specific target genes or genomic re-
gions identified in initial methylome analyses.
The BSAS method demonstrated the utility of the
Nextera XT NGS library generation technology, which
greatly reduces the amount of input DNA (1 ng), decreases
library generation time (approximately 2 to 4 h), and in-
creases the throughput of library generation by performing
the protocol in a 96-well plate. Tagmentation also removes
the need for stepwise DNA shearing, end repair, 3’
adenylation, and adapter ligation, combining these steps
into one. The feasibility and benefits of tagmentation-
based library preparations have been discussed previously
[25]. Another benefit of NGS and Nextera XT library
generation is the dual indexing libraries. Dual indexing
allowed for a high level of sample multiplexing; 96 sam-
ples are capable of being multiplexed onto 1 single-lane
flow cell. Within each sample, multiple target regions can
be analyzed. The high level of multiplexing possible with
BSAS, both in number of samples and regions of interest,
increases the throughput over traditional methods. The
current cost of tagmentation-based library construction is
lower compared to ligation-based library construction
methods. Provided sufficient flow-cell capacity, with BSAS
additional time and costs are limited with increasing sam-
ple size. By comparison, Sanger and pyrosequencing re-
quire significant time and cost for each additional sample.
Supplemental to the simpler and more rapid library
generation, we established the utility of the Illumina MiSeq
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ports have used the MiSeq for high output cytosine modifi-
cation validation [26] or comparing with traditional NGS
library construction methods [25] we show the MiSeq as a
tool for precise orthogonal absolute 5-mC quantitation and
validation. The increased availability, short run times, and
low cost of running benchtop sequencers make them an
attractive tool for targeted analyses. The Illumina Miseq is
currently capable of generating up to 15 Gb of sequence
and 50 million paired-end reads passing quality filters on a
single-lane flow cell. Additionally, sensitive optics and
more precise base calling allow for low-diversity samples
to be sequenced on the MiSeq. This decreases the amount
of control libraries, like PhiX, that have to be added to im-
prove base calling diversity, and reduces the amount of
sequence lost to control sequences. Based on the per-
formance of the method and the most conservative error
rate model, more than 2 kb of target region(s) in 96 sam-
ples can be analyzed with high accuracy with 1 flow cell
in a week by this method. Our findings show the utility
of the MiSeq in future targeted epigenetic studies. Not
only can the MiSeq generate enough data to sufficiently
and accurately quantify DNA methylation, it can also
be scaled in a cost-effective manner, depending on the
amount of sequence (for example, number of samples,
targets, and size of targets) through the use of the differ-
ent size single-lane flow cells. Additionally, the ability of
the MiSeq base-calling algorithms to handle low diversity
samples, make it an excellent tool for sequencing bisulfite-
converted, cytosine deficient DNA.
Limitations of the BSAS method, as described here,
could arise from (1) PCR bias in the original bisulfite
specific PCR, (2) bias in the transposome-mediated DNA
fragmentation and adapter ligation, (3) and the inability of
BSAS to distinguish between 5-mC and 5-hmC. PCR bias
is not an issue when primers are generated properly. Pa-
rameters for designing bisulfite PCR primers that avoid
bias have been addressed in the literature [27]. In our
method, we observed no PCR bias in the data presented.
Upon quantitative methylation analysis of the CpG sites
targeted here, there was also no bias in the strand direc-
tion of the called variants. Additionally, the counts at the
CpG sites were required to be in both the forward and re-
verse reads. Furthermore, we observed no GC bias in the
tagmentation reaction within our amplicons sequenced
using the Nextera XT protocol. As a result of targeting
genomic regions, GC bias is less likely to occur. Previous
studies validating the tagmentation-based library gener-
ation protocol demonstrated no GC bias in transposome
tagmentation [28]. Additionally, previous studies have
shown no differential GC bias between traditional ligation
chemistry-based library generation methods when com-
pared to tagmentation-based methods with bisulfite con-
version [25]. The limitation of this method is the drop offin sequence depth at the end of the amplicons sequenced.
This was attributed to the reduced likelihood of the
transposome to insert at the ends of the amplicons. Fi-
nally, BSAS does not allow the quantitation of both 5-mC
and 5-hmC. Our analysis may include both of these modi-
fications. Future modifications of the protocol to be able
to distinguish from these two modifications will be benefi-
cial as studies of epigenetics progress. For example, the
use of oxidizing agents, or glucosylation coupled to bisul-
fite conversion and analysis through the BSAS for separate
5-mC and 5-hmC quantitation [29,30].
Conclusions
The BSAS method performed absolute 5-mC quantita-
tion with high precision and accuracy, when compared
to a traditional bisulfite sequencing method. Because of
its targeted approach, highly quantitative data output,
and high-throughput capabilities this method will be
valuable in hypothesis driven epigenetic studies needing
to investigate methylation changes in selected genomic
regions where base resolution, high sample throughput
and high quantitative accuracy is required.
Methods
DNA bisulfite conversion and bisulfite specific PCR
Nucleic acid was isolated from mouse retina and
mouse cerebellum according to manufacturer’s protocol
using Qiagen All-prep DNA/RNA coisolation (Qiagen,
Germantown MD, USA). The Penn State animal facilities
are fully accredited by the Association for Assessment and
Accreditation of Laboratory Animal Care, and all animal
procedures were approved by the Institutional Animal
Care and Use Committee in compliance with the Public
Health Service Policy on Humane Care and Use of La-
boratory Animals and the National Research Council's
Guide for the Care and Use of Laboratory Animals. DNA
and RNA was quality checked by 260/280 absorbance
ratio (E Nanovue spectrophotometer (GE Lifesciences,
Uppsala, Swenden)). DNA was quantified using a fluo-
rometric nucleic acid dye (Picogreen, Invitrogen/Life
Technologies, Eugene, OR, USA) according to the manu-
facturer’s protocol and measured on a Spectromax M2
plate reader (Molecular Devices, Sunnyvale CA, USA).
Whole genome enzymatically CpG dinucleotide meth-
ylated rat and mouse methylation controls were obtained
from EpigenDx at mixed ratios (0% and 100%) of 0%,
5%, 10%, 25%, 75% and 100% methylation at 50 ng/μl
(EpigenDx, Hopkinton, MA, USA). Controls methylation
percentages are confirmed using pyrosequencing on gene-
specific regions and global methylation assays. In all, 200
ng of methylated controls or 1 μg of genomic DNA (rat or
mouse) were bisulfite converted using EZ DNA Methyla-
tion according to manufacturer’s protocol (Zymo Research,
Irvine, CA, USA). Briefly, DNA was bisulfite converted for
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no effect on bisulfite conversion efficiency, data not shown)
and subsequently desulfonated, washed, and eluted in 10 μl
elution buffer.
To amplify the Oprm1 promoter region (-145 to +88
relative to transcriptional start site (TSS)) from the
rat genome and Rho promoter region (-283 to +37
relative to TSS) from the mouse genome from bisul-
fite converted DNA the following primer sequences were
used; rat Oprm1-F 5’-TTTTGGTTTTATTAGGGTTG-3’,
rat Oprm1-R 5’-ACCAAAAACCAAATACTAAA-3’ [31],
mouse Rho-F 5’-GAGATATTTTTTTTTTTTTTTATTT
AAGGG-3’, mouse Rho-R 5’-AAAACACATAAAAATTA
AAACCCTCTA-3’ [32]. PCR amplification of these re-
gions was achieved by using ZymoTaq DNA polymerase, a
DNA polymerase capable of amplifying low diversity DNA,
specifically bisulfite converted DNA (Zymo Research,
Irvine, CA, USA). Reactions were performed per manufac-
turer’s suggestions in 50 μl total volumes; 25 μl 2 × reac-
tion buffer, 0.5 μl dNTP mix, 5 μl 10 μM forward and
reverse rat Oprm1 primers, 2.5 μl 10 μM forward and re-
verse mouse Rho primers, 1 to 2 μl bisulfite template
DNA, 0.4 μl ZymoTaq DNA polymerase, and ddH2O to
50 μl. Reaction conditions were: (1) Initial denaturation
at 95°C for 10 minutes, (2) denaturation at 95°C for 30 s,
(3) annealing at 44°C (rat Oprm1) or 50.1°C (mouse Rho)
for 30 s, (4) extension at 72°C for 30 s, 35 cycles (steps
2 to 4), (5) final extension at 72°C for 7 minutes, and
(6) and 4°C hold using a Mastercycler thermal cycler
(Eppendorf, Hauppauge, NY, USA).
PCR products were purified by QIAquick PCR col-
umns, to eliminate primers and enzymes, and eluted
in 30 μl elution buffer (Qiagen, Germantown, MD,
USA). PCR products were quantified using Picogreen
(Invitrogen/Life Technologies, Eugene, OR, USA) fluoro-
metric nucleic acid quantitation and measured on a
Spectromax M2 plate reader (Molecular Devices, Sunnyvale
CA, USA). PCR product sizes were confirmed through
polyacrylamide gel electrophoresis on 6% Novex PAGE gels
(Invitrogen/Life Technologies, Carlsbad, CA, USA). To
visualize products, gels were soaked in ethidium bromide
(0.5 μg/ml in ddH2O) and imaged on a Typhoon 9410
fluorescent scanner (GE Biosciences, Uppsala Sweden) at
532 nm excitation and 610 BP 30 emission filter.
NGS library preparation
Dual indexed libraries were generated using Nextera XT
library preparation technology according to manufac-
turer’s protocol (Illumina, San Diego, CA, USA). Purified
PCR products were diluted to 0.2 ng/μl, and a total of 1 ng
was used for library generation in a 96-well plate format.
Transposome-mediated simultaneous DNA fragmentation
and adapter ligation, that is, tagmentation, was performed
at 55°C for 5 minutes. After the tagmentation reaction,indexing specific PCR primers were added two per well for
unique dual indexing of the libraries for multiplex sequen-
cing. Limited cycle-number PCR was performed to amplify
the libraries and incorporate the index sequences to the li-
braries using the following reaction conditions; (1) 72°C for
3 minutes, (2) 95°C for 30 s, (3) 95°C for 10 s, (4) 55°C
for 30 s, (5) 72°C for 30 s, 11 cycles (steps 3 to 5),
(6) 72°C for 5 minutes, and hold at 10°C. Amplified li-
braries were purified using 30 to 50 μl AMPure XP
beads (Beckman-Coulter, Brea, CA, USA), and eluted
off the beads in 52.5 μl resuspension buffer (provided
with Nextera XT).
Double-stranded libraries were quality checked on a
High Sensitivity DNA Agilent chip run on the Agilent
2100 Bioanalyzer (Agilent Technologies) for size and
molarity determination. Based on these metrics, libraries
were diluted to 650 pM to 2 nM in 10 mM Tris with
0.5% Tween. Equimolar libraries were pooled in equal
volumes for denaturation and dilution in HT1 (Illumina,
San Diego, CA, USA) buffer. Briefly, 10 μl of pooled NGS
library was mixed with 10 μl 0.2 N NaOH for 5 minutes,
then the library was diluted to 20 pM in HT1 buffer. PhiX
control libraries (Illumina, San Diego, CA, USA) were used
to increase diversity of base calling during sequencing.
Then, 10 nM stock of PhiX library was denatured in 0.2 N
NaOH, then diluted to 20 pM in HT1 buffer. At this time,
diluted, multiplexed libraries were mixed with diluted PhiX
at 4:1 volume ratios. A final dilution to 8 to 12 pM was
performed with HT1 buffer for a final volume of 1 ml. A
volume of 600 μl was loaded onto the reagent cartridge
for sequencing.
Sequencing on Illumina MiSeq
Denatured and diluted libraries were sequenced on the
Illumina MiSeq benchtop sequencer with the sequencing-
by-synthesis technology per manufacturer’s protocol.
Runs were set for ‘Generate FASTQ only’ workflow
in Illumina Experiment Manager (Illumina, San Diego,
CA, USA). Then, 300-cycle MiSeq v.1 reagent car-
tridges (Illumina, San Diego, CA, USA) were used to
sequence libraries with paired-end, dual-indexing 151 cy-
cles per read (2 × 151). Sequencing run monitoring was
achieved through BaseSpace beta (basespace.illumina.com)
(Additional file 3: Table S1). Data was demultiplexed on
the MiSeq instrument automatically, and zipped FASTQ
files were generated per sample, per read. Data was ac-
cessed either in the run analysis folder locally on the in-
strument, or through BaseSpace beta.
NGS data analysis and digital methylation quantitation
FASTQ files were imported into CLC Genomics Work-
bench 5.5.2 or 6.0.2 (CLC Bio, Cambridge, MA, USA) as
paired-end data retaining quality scores (NCBI/Sanger
or Illumina 1.8 pipeline or later). A data analysis workflow
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methylation data analysis (Additional file 4: Figure S1).
This workflow includes the following processes; paired-end
overlapping read merge, read trimming on quality score
(only reads containing base calls ≥Q30) and removal of
reads with ≥1 ambiguous nucleotide. Merged and trimmed
reads were then aligned to corresponding reference se-
quences that were bisulfite-converted in silico to allow
stringent read alignment parameters in read mapping
(C nucleotides remained in CpG dinucleotides for reads
containing low methylation percentages). Mapping pa-
rameters were set up to score mismatches, insertions,
and deletions at the highest possible penalty at a cost of 3
for each, with a nucleotide match always being a cost of
1. These scored reads were then filtered based on the
minimum fraction of the read length that mapped to the
reference, at 1, and minimum fraction of identity be-
tween the read and the reference, set to 0.9. These map-
ping parameters allowed for the retention of high-quality
reads containing the majority of differences at CpG di-
nucleotide locations only. The bisulfite conversion effi-
ciency was determined by the ratio of cytosine bases to
converted reference thymine positions. Read mappings
were ran through probabilistic variant detection analysis
for measurement of C frequency in CpG positions, which
correspond to the percentage of cytosine methylation.
Analysis of data was the same between the 5.5.2 and 6.0.2
versions of CLC Genomics Workbench, with the excep-
tion of the variant calling analysis. Because version 6.0.2
calls variance dependent on linkage, two adjacent CpG
sites would be measured as the same level of methylation,
or cytosine frequency. The 5.5.2 version variant caller
identifies variants independent of linkage, an important
aspect of calling cytosine frequency for quantitation of
adjacent CpG sites.
Sanger sequencing and analog methylation analysis
PCR amplicons were sequenced by the Sanger method.
Regions of interest were amplified using the same
primers used in the bisulfite PCR with chain-terminating
fluorescent dideoxy nucleotides. These products were
then sequenced with an ABI 3130XL Capillary sequencer
(Applied Biosystems/Life Technologies, Foster City, CA).
Chromatogram traces (.abi) were analyzed using ESME,
an automated open-source Sanger methylation data
analysis software package developed for the Human
Epigenome Project [13]. This software only analyzes CpG
dinucleotides and measures intensity by the area under
the curve from both the thymine trace and the cytosine
trace, calculating the percentage of cytosine methylation
by the value of cytosine intensity divided by the total in-
tensity. It was developed for analyzing methylation for dir-
ect bisulfite PCR sequencing (http://www.epigenome.org/
index.php?page=download).qPCR
qPCR analysis was performed as described previously
[33,34] using the 7900HT Sequence Detection System
(Applied Biosystems/Life Technologies, Foster City, CA),
384-well optical plates, and Assay-On-Demand (Applied
Biosystems/Life Technologies, Foster City, CA) gene spe-
cific primers and probes (Mm Rho: Mm01184405_m1).
SDS 2.2.2 software and the 2-ΔΔCt analysis method were
used to quantitate relative amounts of product using
β-actin as an endogenous control. β-Actin levels were de-
termined to be unchanged in an absolute quantitation ex-
periment (data not shown).Statistics
Statistical analysis was performed using the standard
parametric t test (α = 0.05, two tailed). An approximate
confidence interval for sequence saturation is derived




, where μ is a given standard methylation ratio,
and n is the number of sequenced reads covering the re-
gion of interest. Mean squared error (MSE) accuracy as-
sessment was performed on quantified methylation
controls to compare between BSAS and Sanger/ESME.
To perform the MSE analysis, the methylation controls
were assumed to be correct. The MSE ratio of the
Sanger/ESME to BSAS quantitation methods were calcu-
lated and reported.
For the BSAS method, triplicate runs allow for an em-
pirical calculation of a confidence interval for saturation
along an amplicon with variable depths of sequenced
reads. The empirical calculations are compared to confi-
dence intervals based on the binomial probability model;
for a standard methylation ratio of 0.5, the binomial-based
confidence interval reduces to 0.5  1ﬃﬃnp . The confidence in-
tervals for varying sequencing depths were calculated and
plotted.Additional files
Additional file 1: Figure S2. Depth plots across mouse and rat
amplicons for bisulfite amplicon sequencing (BSAS). (A) Average
sequencing depth plots across mouse amplicon and (B) rat amplicon for
each methylation standard. Relative location along amplicon in reference
to transcription start site.
Additional file 2: Figure S3. Theoretical and empirical binomial model
for methylation quantitation confidence interval radii of mouse
methylation standards. Average empirical confidence interval radius is
0.0046, within the theoretical confidence interval radius. Average
difference between the theoretical and empirical confidence interval was






μ is the methylation percentage and n is the sequencing depth.
Additional file 3: Table S1. MiSeq run summaries. Single lane flow cell
cluster densities, the percentage clusters passing filter, total paired reads
passing filter, and total percentage reads above Q30.
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http://www.epigeneticsandchromatin.com/content/6/1/33Additional file 4: Figure S1. Methylation quantitation workflow
schematic. FastQ files are imported for workflow input. Reads are then
merged to eliminate overlapping pairs. Sequences are then quality
trimmed and mapped to a reference sequence. Variant detection is used
to identify CpG sites and the percentage of cytosine methylation.
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